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In Vitro Anti-Atherogenic Properties of N-Heterocyclic Carbene 
Aurate(I) Compounds 
Eleni Sioriki,[a] Ronan Lordan,[b] Fady Nahra,[a] Kristof Van Hecke,[a] Ioannis Zabetakis,[b]* and Steven P. 
Nolan[a][c]* 
Abstract: The anti-atherogenic (anti-inflammatory) properties of 
various aurate(I) salts, of the general formula [NHC·H][AuCl2] (NHC 
= N-heterocyclic carbene) have been investigated. The aurates are 
easily synthesized and obtained in analytically pure form. In addition, 
the biological activity of these compounds against atheromatosis via 
in vitro inhibition of platelet-activating factor (PAF) induced platelet 
aggregation was probed. All complexes were found to possess anti-
aggregatory properties in vitro with [IPr*·H][AuCl2] 6 being the most 
potent inhibitor of PAF in micromolar concentration. Based on our 
findings, we conclude that these simply assembled aurates are a 
very promising class of PAF-inhibitors and anti-inflammatory drugs. 
With the projected increase in world population and increased 
life-expectancy, chronic diseases and especially cardiovascular 
diseases (CVD) have become the most important leading 
causes of death, worldwide.[1] CVD is likely to reach epidemic 
proportions in the coming decades.[2,3] These chronic 
multifactorial inflammatory diseases are characterized by the 
development of lesions on the intima wall of medium and large-
sized arteries, called atheromata or atherosclerotic plaques. 
After decades of lethargic progression, these lesions progress 
suddenly and cause stenosis, thus limiting blood-flow or even 
arterial rupture causing characteristic clinical manifestations 
such as distal ischemia, progressive clot formation, and stroke.[4] 
 One of the most potent mediators of inflammation that 
plays a crucial role in atherosclerosis is platelet-activating factor 
(PAF) (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine);[5] which 
is a well-established biologically active glyceryl-ether 
phospholipid with 16-18 carbons at sn-1 position of the glycerol 
backbone (Figure 1).[5] PAF modulates angiogenesis, 
thrombosis, oncogenic transformation, tumor growth, metastasis 
and the mechanism of atherogenesis (atheromatosis).[4-6] PAF is 
considered to be a primitive and global cellular bio-regulator[5,8,9] 
that was initially recognized from its potential cumulative action 
to platelets but intense studies have shown a broader potent 
biological activity in numerous cell types and tissues.[10–12]  
 PAF exerts its biological actions through a unique seven-
transmembrane G-protein-coupled receptor known as the PAF-
receptor (PAF-R) located on the plasma membrane of a wide 
variety of mammalian cells, such as leukocytes, neutrophils, 
platelets, macrophages and endothelial cells.[13,14] PAF and PAF-
like molecules are specific, structurally-defined ligands that 
exclusively bind to PAF-R with exceedingly high affinity.[15–17] 
Engagement of the PAF-R by PAF or PAF-like lipids triggers an 
assortment of intracellular signalling cascades. This initiates 
biochemical mechanisms that induces functional responses of 
PAF-R bearing cells that then initiate or amplify inflammatory 
and thrombotic events.[18] 
 
Figure 1. Chemical structure of PAF (1-O-alkyl-2-acetyl-sn-glycero-3-
phosphocholine)[5] 
 PAF induced inflammatory processes are intensely 
involved in the initiation and progression of atherosclerosis. [6] 
PAF is also involved in coronary artery constriction, modulation 
of myocardial contractility, and the generation of arrhythmias, 
which relate to cardiac disorders such as ischemia, infarction, 
and sudden cardiac death.[19,20] Mediators of inflammation play 
an important role in maintaining a balance in an acute 
inflammatory response. Therefore, many biochemical and 
enzymatic markers have been suggested for the determination 
of inflammation and cardiovascular disease.[21] Synthetic PAF-
inhibitors, such as Rupatadine[22] and natural dietary sources[7,23] 
have demonstrated their ability to inhibit PAF-induced platelet 
aggregation in washed rabbit platelets and in human platelets.  
 Transition metal compounds have a wide range of medical 
applications. Platinum, palladium, ruthenium, and gold metal 
complexes have been synthesised by the pharmaceutical 
industry for a number of medicinal applications that include anti-
viral, anti-bacterial, anti-rheumatic and anti-inflammatory 
efficacy.[24] Metals were first used 50 years ago, when Cisplatin 
(cis-diamminedichloroplatinum(II)) was shown to inhibit cellular 
division in Escherichia coli and was later studied for its anti-
tumor activity.[25,26] Cisplatin has since been shown to inhibit 
PAF-induced platelet aggregation.[27] Previous research on gold 
metal complexes has shown that they also possess putative 
bioactivities that may be useful in medicinal applications, 
particularly in relation to cancer treatment.[28,29] To date, only two 
gold salts have been developed for medicinal purposes, 
Au(I)thiolate and auranofin (Au(I)-thiolate triethylphosphine), 
which have been used in the treatment of rheumatoid 
arthritis.[28,30] Other complexes have not yet entered clinical trial 
due to their high cardiotoxicity.[24] 
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 Previous studies have shown that metal complexes, such 
as square planar rhodium(I) organometallic complexes and a 
series of novel octahedral rhodium(III) complexes possess 
potent antithrombotic properties.[27] Recently, NHC-based (NHC 
= N-heterocyclic carbene) complexes have attracted substantial 
interest as these compounds possess broad applications in the 
field of medicine.[31] NHC ligands, are neutral 2-electron donors, 
that have been extensively used to stabilize organometallic 
species due to their strong donating properties and tunable 
steric bulk.[32] In the particular case of gold complexes, the use 
of NHC ligands has allowed for the isolation of typically unstable 
species and for the development of highly active homogeneous 
catalysts.[33] As we have significant expertise in the area of 
NHCs, of transition-metal bearing NHC ligands and their uses, 
we sought to investigate the potential anti-atherogenic properties 
of various recently synthesized aurate(I)-NHC salts as well as 
evaluate their in vitro biological activities against PAF induced 
platelet aggregation. 
 As it is clear that PAF plays a critical role in inflammatory 
processes, the promising results of PAF inhibitor studies evoke 
the need for the development of more synthetic PAF inhibitors. 
In this study, nine gold complexes (1-9) were synthesized and 
fully characterized via NMR spectroscopy, elemental analysis 
and mass spectroscopy (Scheme 1). Furthermore, single 
crystals of complexes 4, 7 and 9 were grown and their molecular 
structures were unambiguously elucidated via X-ray diffraction 
analysis (Figure 2). All complexes were air and moisture stable, 
with the exception of 4, which decomposed upon prolonged 
exposure to air. Thus, this complex was excluded from the 
present biological assays.  
 
 
Scheme 1. Gold-imidazoli(ni)um, gold-NHC complexes and Imidazolium 
evaluated for biological activity against PAF. 
 
 All gold(I) complexes were synthesised according to our 
previously reported simple procedure (Scheme 1).[34] X-ray 
analysis of complexes 4, 7 and 9 showed that the aurates were 
indeed formed with a linear [Cl-Au-Cl]- anion in all cases, along 
with the [NHC.H]+ as the counter-cation.[35] The family of 
complexes consists of simple anion/cation pairs where the 
cation is a saturated or unsaturated imidazole-based heterocycle 
bearing either alkyl or aryl groups of various size on the 
heterocyclic nitrogens.  
 
Figure 2. Thermal ellipsoid representations of complexes 4, 7 and 9 (from left 
to right) at 50% probability. Solvent molecules and all hydrogen atoms are 
omitted for clarity. 
 The putative antithrombotic and anti-inflammatory effects 
of novel gold N-heterocyclic carbene complexes were next 
assessed. Previous reports have shown that metal complexes 
can inhibit PAF-induced platelet aggregation in washed rabbit 
platelets (WRP) and rabbit platelet-rich plasma (PRP) in vitro 
through the PAF receptor dependent pathway.[27] All of the gold 
compounds tested in this study possessed strong antithrombotic 
activity as indicated by their IC50 value expressed in µM (Table 
1), thus confirming that these simple gold metal complexes can 
inhibit PAF-induced platelet aggregation on human platelets in 
vitro. 
Table 1. Inhibition of PAF-induced platelet aggregation in human PRP by gold 
metal complexes (mean ± SD, n = 3).  
 
Metal Complex Formula IC50 (µM) (mean ± SD, n =3) 
1 [IPr·H][AuCl2] 2.01 ± 0.15b 
2 [SIPr·H][AuCl2] 2.96 ± 0.76c 
3 [IMes·H][AuCl2] 1.67 ± 0.15b 
5 [IPent·H][AuCl2] 1.62 ± 0.36b 
6 [IPr*·H][AuCl2] 0.98 ± 0.24a 
7 [IPr*OMe·H][AuCl2] 1.66 ± 0.38b 







1.69 ± 0.31b 
3.52 ± 1.39c 
515.49 ± 102.58d 
 a,b,c,d Values with similar superscripts indicate no significant statistical 
difference; different superscripts indicate significant differences among the 
different metal complexes (P<0.05) when means are compared using a 
Fisher’s LSD multiple comparison test. 
  
 The IC50 values reflect the inhibitory strength of each 
compound towards PAF induced platelet aggregation (Table 1). 
A low IC50 value indicates a strong inhibitory effect against PAF 
for a given concentration of the metal complexes. The 
complexes synthesized in this study have displayed varying 
levels of inhibition against the interactions of PAF and the PAF-
R in human platelets. As can be seen in Table 1, complex 6 
exhibited the lowest IC50 value (0.98 µM ± 0.24) indicating that 
this complex was the most potent against PAF-induced platelet 
aggregation. The IC50 value for c 6 was significantly different 
from all other complexes. Furthermore, when comparing the IC50 
of 1, 3, 5, 7, 8, and 9, no significant difference is noticed. These 
similar IC50 values may be due to the fact that there are only 
subtle structural and electronic differences between these 
complexes that lead to similar antithrombotic activity; it appears 
that alkyl or aryl substituents on the nitrogen atoms do not 
significantly influence the change in activity. However, when 
comparing 6 to the closely related 7, we see a significantly 
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electronic effects and/or solubility issues (since the difference 
between 6 and 7 lies mainly in their electronic properties). The 
presence of a methoxy group may account for this difference as 
the lies at the periphery of the complex and may affect solubility 
in the biological medium.[36] In contrast, complex 2 had a much 
higher IC50 value than all other aurates in this study; this could 
be due to the noticeable change in electronic properties since 
this is the only complex bearing a saturated backbone. These 
data indicate that major electronic variations, especially on the 
NHC backbone, could be key for further developments in future 
aurate-NHC drug design. These avenues are presently being 
explored in our laboratories. 
 Two other compounds were tested to quantify any 
background activity for ligand and neutral complexes. 
Compound A, [IPr•HCl], was examined to study the activity, if 
any, of the imidazolium ligand and compound B, [AuCl(IPr)], to 
model the neutral Au(I) system.[28,29,34] Compound A contains the 
IPr core without the gold moiety (only Cl- as counterion; this will 
serve as a blank and will thus allow us to confirm the need for 
the gold moiety when compared to its close counterpart complex 
1) and compound B represents another class of gold complexes 
that have shown potential in previous biological studies, though 
having lower activity than the aurate-class showcased herein. It 
is clear from Table 1 that compound B was far less potent than 
the other complexes (515.49 µM ± 102.58), however this 
compound possessed a relatively low IC50 in comparison to 
those tested on WRP in the literature. In contrast compound A 
demonstrated a lower IC50 (3.52 µM ± 1.39) than compound B; 
however, this is still higher than all the other aurate complexes.   
 These data highlight the important difference between the 
various classes of NHC compounds studied herein (NHC-
aurates 1-9 vs gold-NHC compound B vs gold-free imidazolium 
compound A), where the combination of the gold moiety and 
NHC salt present in the aurates seems to be crucial for higher 
activity. To the best of our knowledge, metal complexes have 
not been tested in human PRP; therefore, for the first time, this 
study has confirmed that these gold complexes possess anti-
aggregatory properties against PAF-induced platelet 
aggregation in vitro.  
 In previous research, WRP were the preferred method of 
platelet aggregometry studies, due to their stability and longevity 
while testing. Rabbit platelets also exhibit similar physiological 
modes of platelet activation and aggregation to human platelets, 
and thus is one of the main experimental models of choice to 
replicate human platelets.[37,38] Therefore, the observed IC50 
values of the studied gold complexes against PAF-induced 
platelet aggregation can cautiously be compared with the IC50 
values of metal complexes determined using rabbit PRP and 
WRP in previous studies. The obtained IC50 values of the 
aurates are within range of the IC50 values determined in studies 
of rhodium and ruthenium metal complexes by PAF-induced 
platelet aggregation in WRP. Rhodium complexes possessed 
IC50 values of 0.015 - 2.6 µM in WRP, and IC50 values of 18 - 
582 µM in rabbit PRP, whereas ruthenium complexes had IC50 
values ranging from 0.18 – 11.8 µM in WRP and 10.5 – 900 µM 
in rabbit PRP.[27,38] Of note, the iridium and ruthenium complexes 
are obtained through multistep synthetic routes whereas the 
present gold complexes are obtained after simply mixing a gold 
precursor and a commercially available (or synthetically 
straightforwardly obtained) imidazolium salt. Interestingly, the 
NHC-aurates presented here inhibit PAF-induced platelet 
aggregation to the same order of magnitude of known natural 
and pharmaceutical PAF antagonists, namely Web 2170 
(Bepafant), BN 52021 (Ginkgolide B), Cedrol and Rupatadine 
(0.02 µM, 3.6 µM, 13 µM and 0.26 µM respectively in WRP).[39–
44] Therefore, these gold complexes may be viable for further 
research and development for the purpose of anti-inflammatory 
therapeutic agents for non-communicable diseases such as 
cardiovascular disease and cancer. Further in vivo, ex vivo, and 
clinical research is required in order to establish the efficacy of 
these compounds as therapeutic agents.  
 PAF orchestrates its biological activity through a specific 
seven-transmembrane receptor coupled with G-proteins (PAF-
R). Therefore, it is proposed that these gold compounds may 
possess anti-inflammatory and anti-atherogenic effects. PAF-R 
antagonists have exhibited promising results in vitro and in vivo 
as anti-angiogenic molecules in several cancer cells and 
tumors.[45] Gold complexes similar to those tested in this study, 
have already exhibited anti-inflammatory activity (respiratory 
burst assay) and cytotoxicity against HeLa (cervical cancer), 
MCF-3 (breast cancer), and 3T3 (mouse fibroblast) cell lines.[29] 
Notably, PAF has been implicated in coordinating angiogenesis, 
oncogenic transformation, tumour growth, and metastasis in 
cancer (AA). Research has shown that PAF plays a significant 
metastatic role in difficult to treat cancers such as melanoma, 
where it has shown to promote metastasis in vivo. Furthermore, 
it has been demonstrated that the PAF-R antagonist PCA4248 
has inhibited experimental human melanoma lung metastasis in 
nude mice.[46] Therefore, as similar gold complexes to those 
synthesized for this study possess anti-cancer activity,[28,29] 
further research on the antagonistic actions of the herein 
presented aurates against the PAF-R is warranted and currently 
ongoing in our group, as they are potentially powerful anti-
metastatic agents.  
 In summary, the present work has evaluated for the first 
time the structural and potent antithrombotic properties of gold 
N-heterocyclic carbene complexes towards PAF-induced 
aggregation of human PRP, at concentrations comparable with 
those of classical PAF-inhibitors. The simple and atom-
economical synthetic route to these aurates renders them   
attractive from an accessibility perspective. The inhibitory effect 
of all aurate compounds was tested and expressed by their IC50 
value in μM. All complexes were found to possess anti-
aggregatory properties in vitro with 6 being the most potent 
inhibitor of PAF in micromolar concentration. Based on our 
findings, we can conclude that these aurates are indeed a very 
promising class of PAF-inhibitors and anti-inflammatory drugs. 
Further investigations into molecular design are ongoing with the 
aim of reaching even higher levels of efficacy in the in vitro 
biological activity detailed in this study. 
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